Advances in Therapy

, Volume 28, Issue 4, pp 304–310

First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony- stimulating factor

Authors

    • Service de BiothérapieGroupe Hospitalier Necker-Enfants Malades
    • Service de Biothérapie, H≪tal NeckerAPHP
  • Anne-Colette Brignier
    • Service de Biothérapie, H≪tal NeckerAPHP
  • Caroline Elie
    • Service de Biostatique, Hôpital Necker, APHPUniversité Paris Descartes
  • Jean-Antoine Ribeil
    • Service de Biothérapie, H≪tal NeckerAPHP
  • Michael Bernimoulin
    • Service de Biothérapie, H≪tal NeckerAPHP
  • Charbel Aoun
    • Service de Biothérapie, H≪tal NeckerAPHP
  • Liliane Dal Cortivo
    • Service de Biothérapie, H≪tal NeckerAPHP
  • Richard Delarue
    • Service d’Hématologie Adultes, H≪tal NeckerAPHP
  • Olivier Hermine
    • Service d’Hématologie Adultes, H≪tal NeckerAPHP
  • Marina Cavazzana-Calvo
    • Service de Biothérapie, H≪tal NeckerAPHP
Original Research

DOI: 10.1007/s12325-011-0009-1

Cite this article as:
Lefrère, F., Brignier, A., Elie, C. et al. Adv Therapy (2011) 28: 304. doi:10.1007/s12325-011-0009-1

Abstract

Introduction

Mobilization techniques for autologous peripheral blood stem cell (PBSC) collection include chemotherapy followed by hematopoietic growth factors, such as granulocyte colony-stimulating factor (G-CSF). Biosimilar versions of G-CSF are now available in Europe.

Methods

In this study, 40 patients with a hematological malignancy scheduled to receive biosimilar G-CSF (Zarzio® Sandoz Biopharmaceuticals, Paris, France) following first-cycle chemotherapy for treatment and autologous PBSC mobilization were prospectively included at a single center. These patients were compared with a historical control group who had been treated with G-CSF (Neupogen® Paris, France) at the same center according to the same clinical protocol. PBSC harvesting was considered successful if at least 3×106 CD34+ cells/kg were collected. If three consecutive CD34+ tests were below 10/μL then PBSC harvesting was not performed.

Results

Patient characteristics were similar in both groups with no significant differences in age, diagnosis, previous chemotherapy, or chemotherapy mobilization regimen. No significant differences were observed between groups in median CD34+ cells mobilized and collected, or the number of G-CSF injections and leukaphereses required to obtain the minimal CD34+ cell count. Proportion of failures was also similar in both groups.

Conclusion

Zarziois® comparable to Neupogen® for PBSC mobilization and collection after chemotherapy and so may provide a more cost-effective strategy.

Keywords

autologous transplantationbiosimilarsG-CSFhematological malignanciesleukapheresisstem cell mobilizationZarzio

Copyright information

© Springer Healthcare 2011